Ignite Creation Date:
2024-05-06 @ 2:46 PM
Last Modification Date:
2024-10-26 @ 1:37 PM
Study NCT ID:
NCT04425200
Status:
COMPLETED
Last Update Posted:
2021-12-07
First Post:
2020-05-21
Brief Title:
Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer mCRPC Patients in Real World Setting
Sponsor:
Organization:
AstraZeneca
Study Design
Study Type:
OBSERVATIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
False
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
SAMPLES_WITH_DNA
Bio Spec Description:
An archived formalin fixed paraffin embedded FFPE sample ten slides and 10 μm in thickness on uncharged slide be used for HRR-related gene mutation testing in principle And also ten 10 μm slides is sent to Myriad with one 3-5 micron on a charge slide for the HE stainingHematoxylin and eosin staining which is continuous with the slice for HRR-related gene mutation These contents include with a sample of 25 mm2 in section area containing a 30 tumor nuclei preferred 20 tumor nuclei accepted If patients have some tumor samples at multiple points the latest sample is preferred to use HRR-related gene mutation testing And other tumor sample is acceptable to use HRR-related gene mutation testing if test is failed
Enrollment Count:
205
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
Observational Models:
| Name |
|---|
| Cohort |
Time Perspective List:
Clinical Trial Statuses
| Name |
|---|
| 65727 |
Who Masked List: